Integra welcomes policy advancements supporting Medicare beneficiary access

Integra LifeSciences (IART) commends the Centers for Medicare & Medicaid Services, CMS, on its Calendar Year 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules. All Integra dermal regenerative templates, decellularized dermal scaffolds and amniotic tissue membranes, which are classified as skin substitutes by CMS, are included in the ruling. These products – Integra matrices, PriMatrix, Cytal and AmnioExcel – utilize four different technology platforms for a wide range of complex cases in wound reconstruction.